Beam Therapeutics Inc.
Stock Details
Is it expensive?
Trailing P/E Ratio
-40.65
Forward P/E Ratio
-7.06
PEG Ratio
1.53
-6.60
Price-to-Sales (TTM)
21.00
2.86
11.72
Market Cap
3.39B
2.30B
Is it profitable?
Net Profit Margin (TTM)
-40.23%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-0.49
-5.77%
164.01M
Is it growing?
324.90%
324.87%
Is it risky?
2.26
21.54
16.99
250.82M
Who owns it?
107.04%
1.36%
39.93%
102.74M
87.97M
Does it pay?
0.00%
0.00%
--
--
How much cash?
1.21B
-369.73M
-233.56M
12.17
- Price
- 32.93
- Percent Change
- +0.13 (0.40%)
- Previous Close
- 32.80
- Open
- 32.50
- Low
- 32.20
- High
- 33.66
52-Week Range Position (52WRP)
Expensive
Expensive
within its 1-year price range
$32.93
From 52W Low
+114.53%
From 52W High
-9.63%
Today
+0.40%
1Y Change
+108.02%
6M
$24.05
3M
$28.69
1M
$30.33
Today
$32.93
From 52W Low
+114.53%
From 52W High
-9.63%
Today
+0.40%
1Y Change
+108.02%
6M
$24.05
3M
$28.69
1M
$30.33
Today
$32.93
Expensive
within its 1-year price range
$32.93
Multi-Timeframe Analysis (MTA)
Strong Uptrend
All four timeframes point up. This is the strongest bullish signal. Fully-aligned multi-period trends carry the highest continuation probability. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+8.6%
3M
+14.8%
6M
+36.9%
1Y
+108.0%
Rate of Change (ROC)
Strengthening
Price is rising 1.3x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Beam Therapeutics Inc.
- Founded
- 2017
- CEO
- John M. Evans
- Employees
- 522
- Fiscal Year End
- Dec 31, 2024
- Address
238 Main Street
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.beamtx.com
Indicators
Operating Cash Flow
-369.73M
Net Income
-65.98M
Real Earnings
5.60
Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Related Heatmaps
Cathie WoodPortfolio ARK Investment Management |
Indicators
Operating Cash Flow
-369.73M
Net Income
-65.98M
Real Earnings
5.60
Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
-40.65
Forward P/E Ratio
-7.06
PEG Ratio
1.53
-6.60
Price-to-Sales (TTM)
21.00
2.86
11.72
Market Cap
3.39B
2.30B
Is it profitable?
Net Profit Margin (TTM)
-40.23%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-0.49
-5.77%
164.01M
Is it growing?
324.90%
324.87%
Is it risky?
2.26
21.54
16.99
250.82M
Who owns it?
107.04%
1.36%
39.93%
102.74M
87.97M
Does it pay?
0.00%
0.00%
--
--
How much cash?
1.21B
-369.73M
-233.56M
12.17
- Price
- 32.93
- Percent Change
- +0.13 (0.40%)
- Previous Close
- 32.80
- Open
- 32.50
- Low
- 32.20
- High
- 33.66
52-Week Range Position (52WRP)
Expensive
Expensive
within its 1-year price range
$32.93
From 52W Low
+114.53%
From 52W High
-9.63%
Today
+0.40%
1Y Change
+108.02%
6M
$24.05
3M
$28.69
1M
$30.33
Today
$32.93
From 52W Low
+114.53%
From 52W High
-9.63%
Today
+0.40%
1Y Change
+108.02%
6M
$24.05
3M
$28.69
1M
$30.33
Today
$32.93
Expensive
within its 1-year price range
$32.93
Multi-Timeframe Analysis (MTA)
Strong Uptrend
All four timeframes point up. This is the strongest bullish signal. Fully-aligned multi-period trends carry the highest continuation probability. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+8.6%
3M
+14.8%
6M
+36.9%
1Y
+108.0%
Rate of Change (ROC)
Strengthening
Price is rising 1.3x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Beam Therapeutics Inc.
- Founded
- 2017
- CEO
- John M. Evans
- Employees
- 522
- Fiscal Year End
- Dec 31, 2024
- Address
238 Main Street
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.beamtx.com
Related Heatmaps
Cathie WoodPortfolio ARK Investment Management |